BioCentury | Aug 12, 2020
Deals

Single-asset KaNDy finds $425M exit as Bayer continues to build women’s health portfolio

...companies have NK3R-targeted menopause programs in the clinic. Sojournix Inc. has completed Phase I testing of SJX-653...
BioCentury | Jan 4, 2019
Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

...emerged from stealth with $44 million in series C funding to support clinical development of SJX-653...
...Cabaletta Bio Inc., Radnor, Pa. Sojournix Inc., Waltham, Mass. Thousand Oaks Biopharmaceuticals Inc., Haimen, China Sandi Wong DSG3-CAART SJX-653 Cabaletta...
BioCentury | Jan 3, 2019
Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

...emerged from stealth with $44 million in series C funding to support clinical development of SJX-653...
...Desmoglein 3; NK3R (TACR3) - Neurokinin 3 receptor Sandi Wong DSG3-CAART Cabaletta Bio Inc. Neurokinin 3 receptor (NK3R) (TACR3) Pemphigus hot flashes SJX-653 Sojournix...
Items per page:
1 - 3 of 3